Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, ...

While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s ...

Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. That same day ...

The FDA is signaling change, but actual success depends on more than simply bringing in a new leader at the Center for ...

BioSpace is proud to present its NextGen: Class of 2026, a list of the hottest new life sciences companies in the United States. To come up with this list, BioSpace identified companies that announced ...

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes ...

The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community ...

Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight ...

The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s ...

Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for ...